Metabolic Solutions Development Overview
- Founded
- 2006
- Status
- Private
- Employees
- 13
- Latest Deal Type
- Later Stage VC
- Latest Deal Amount
- $16.3M
- Investors
- 9
Metabolic Solutions Development General Information
Description
Developer of a novel molecular target and therapeutics designed to treat diabetes and related symptoms of metabolic syndrome. The company's therapeutics provide drugs that are used to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially insulin resistance and type 2 diabetes, enabling diabetic patients to get insulin sensitizers.
Contact Information
Website
www.msdrx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
- 161 East Michigan Avenue
- 4th Floor
- Kalamazoo, MI 49007
- United States
Metabolic Solutions Development Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Later Stage VC | 05-Feb-2019 | $16.3M | 0000 | Completed | Generating Revenue | |
| 11. Grant | 01-Jan-2014 | 00000 | 000.00 | Completed | Generating Revenue | |
| 10. Grant | 06-Oct-2011 | 00.00 | 000.00 | Completed | Generating Revenue | |
| 9. Later Stage VC | 10-Aug-2011 | 00.000 | 000.00 | Completed | Generating Revenue | |
| 8. Grant | 06-Jul-2011 | 00000 | 000.00 | Completed | Generating Revenue | |
| 7. Later Stage VC (Series D) | 21-Oct-2010 | 000.00 | 000.00 | Completed | Generating Revenue | |
| 6. Grant | 01-Jan-2010 | 00.000 | 000.00 | Completed | Generating Revenue | |
| 5. Early Stage VC | 30-Apr-2009 | 000.00 | 000.00 | Completed | Generating Revenue | |
| 4. Grant | 01-Jan-2009 | $381K | $15.8M | Completed | Generating Revenue | |
| 3. Early Stage VC | 28-Jan-2008 | $15.8M | $15.8M | Completed | Generating Revenue |
Metabolic Solutions Development Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a novel molecular target and therapeutics designed to treat diabetes and related symptoms of metabolic synd
Drug Discovery
Kalamazoo, MI
13
As of 2022
0000
0000000000 0
0000
0000000
commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu
0000000000000
Cambridge, MA
00
As of 0000
0000
0000
0000-00-00
00000000000
0000
00000000
tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitat
0000 000000000
Cambridge, MA
0
As of 0000
0000
0000000000
0000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialMetabolic Solutions Development Competitors (88)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Navitor Pharmaceuticals | Venture Capital-Backed | Cambridge, MA | 00 | 0000 | 00000000000 | 0000 |
| 00000000 | Venture Capital-Backed | Cambridge, MA | 0 | 0000 | 0000000000 | 0000 |
| 0000000 | Venture Capital-Backed | Cambridge, MA | 000 | 00000000000 | 000 | |
| 0000000 0000000000 | Formerly VC-backed | San Diego, CA | 00 | 00000 | 000000000 | 00000 |
| 000000 00000000000 | Formerly VC-backed | San Diego, CA | 00 | 00000 | 000000&0 | 00000 |
Metabolic Solutions Development Patents
Metabolic Solutions Development Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2016531111-A | Ppar saving compounds for treating metabolic diseases | Granted | 22-Jul-2013 | 0000000000 | |
| US-20160152570-A1 | Ppar-sparing compounds for the treatment of metabolic diseases | Granted | 22-Jul-2013 | 0000000000 | |
| US-9562012-B2 | Ppar-sparing compounds for the treatment of metabolic diseases | Active | 22-Jul-2013 | 0000000000 | |
| CA-2918376-A1 | Ppar-sparing compounds for the treatment of metabolic diseases | Pending | 22-Jul-2013 | 0000000000 | |
| ES-2813363-T3 | Ppar-sparing compounds for the treatment of metabolic diseases | Active | 22-Jul-2013 | C07D213/68 |
Metabolic Solutions Development Executive Team (5)
Metabolic Solutions Development Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Gerald Callahan Ph.D | Michigan Accelerator Fund 1 | Board Member | 000 0000 |
| James Schultz JD | Open Prairie Ventures | Board Member | 000 0000 |
| Mark Olesnavage | Hopen Life Science Ventures | Chairman | 000 0000 |
| Michael Jandernoa | Hopen Life Science Ventures | Board Member | 000 0000 |
| Robert Zerbe MD | Self | Board Member | 000 0000 |
Metabolic Solutions Development Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialMetabolic Solutions Development Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| National Institute on Alcohol Abuse and Alcoholism | Government | 000 0000 | 000000 0 | ||
| National Institutes of Health | Government | 000 0000 | 000000 0 | ||
| Charter Capital Partners | Investment Bank | Minority | 000 0000 | 000000 0 | |
| Hopen Life Science Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Michigan Accelerator Fund 1 | Venture Capital | Minority | 000 0000 | 000000 0 |